InnoCare Pharma
Manufacturing · New Jersey, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
103 Carnegie Ctr Ste 209, Princeton, New...Phone Number
(609) 524-0673Website
www.innocarepharma.comRevenue
$32.5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About InnoCare Pharma
诺诚健华 is focused on developing innovative drugs to address significant unmet clinical needs in the fields of malignant tumors and autoimmune diseases. The company possesses comprehensive research and commercialization capabilities, aiming to create first-in-class or best-in-class therapies for global markets. With a strong pipeline in hematological malignancies, autoimmune diseases, and solid tumors, 诺诚健华 is committed to delivering high-quality innovative medicines that benefit patients worldwide. The company is led by co-founder and CEO Dr. 崔霁松, who emphasizes the importance of scientific-driven innovation.Explore more
InnoCare Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is InnoCare Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if InnoCare Pharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at InnoCare Pharma
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if InnoCare Pharma has recently received funding, and reach out quickly before it becomes old news!
InnoCare Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when InnoCare Pharma launches new products
Click to see if InnoCare Pharma had a recent Job posting/layoffs
Funding: Get notified immidiatlly once InnoCare Pharma has new funding data
Earning: See what the market has to say on InnoCare Pharma recently announced quarterly report
Recommended Actions
Find VP level buyers at InnoCare Pharma
Find 3 more new buyers
Compare Similar Companies to InnoCare Pharma
Compare insights from companies similar to InnoCare Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
InnoCare Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
InnoCare Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about InnoCare Pharma.
InnoCare Pharma financials insights
Gather financial insights about InnoCare Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$288M
InnoCare Pharma Tech Stack
A closer look at the technologies used by InnoCare Pharma
See more technologies
Most Recent Scoops
Hiring Plans
InnoCare Pharma has more open roles in Finance than it has had at any time in the past 12 months. Areas of expertise include: Regulatory Requirements, Corporate Development, Project Status Reports, Resource Allocation, Strategy Execution, Cost Allocation, and Portfolio Management.
Hiring Plans
Hiring Plans
InnoCare Pharma has more open roles in Medical & Health than it has had at any time in the past 12 months. Areas of expertise include: Medical Monitoring, and Clinical Trials.
Hiring Plans
Person-Based
Pharmaceuticals
Person-Based
Pharmaceuticals
Hiring Plans
Hiring Plans
InnoCare Pharma News & Media
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines
InnoCare will receive up to $100 million in upfront and near-term payments, and up to approximately $3.25 billion in milestone payments.InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China
ICP-B381 is InnoCare’s first bispecific ADC to enter the clinic and the third ADC to enter clinical trials.InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved
In the first half of 2026, InnoCare's revenue grew by 55.5% and profit reached RMB 239.7 million, a turnaround from a loss in the same period last year.InnoCare Announces Approval of Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment-Naive AML in China
The registrational Phase III study of the mesutoclax regime versus venetoclax regime in elderly or unfit patients with TN AML has been approved in China.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding InnoCare Pharma
Sign Up For FreeTo access detailed company insights
诺诚健华 is focused on developing innovative drugs to address significant unmet clinical needs in the fields of malignant tumors and autoimmune diseases. The company possesses comprehensive research and commercialization capabilities, aiming to create first-in-class or best-in-class therapies for global markets. With a strong pipeline in hematological... Read More
